In addition, this study found that AG1024 had synergistic effects with doxorubicin even in the doxorubicin-resistant variant of the 143B cell line and increased doxorubicin sensitivity in this cell line [381], suggesting that inhibiting IGF-1R may be useful in treating resistant osteosarcoma. Here, IGF1R is linked to osteosarcoma.